NEW

Top 25 Biotech Companies of 2024

Article originally published on GEN The biotechnology industry achieved many firsts this past year, from the first approved drug that can slow the rates of cognitive and functional decline in adults with Alzheimer’s disease, to the first CRISPR-based gene editing...

Best of CRISPR 2017 Articles

Best of CRISPR 2017

One can hardly pick up a science journal or biotech magazine without reading about another CRISPR-related advance. In the past six months, we have seen major advances in editing disease-causing genes in human embryos. New tools include RNA-editing CRISPR systems and ultra-precise base editors. In the latter, a modified Cas protein pinpoints and tweaks a specific nucleotide, rather than completely cleaving the double helix. In this timely supplement, GEN has compiled a selection of topical features on novel applications that neatly capture the incredible excitement and potential of this technology. Kicking things off is Malorye Branca’s excellent feature exploring clinical applications of CRISPR therapies entitled: “A Dose of CRISPR: Can Gene-Editing Cut It in the Clinic?” (This originally appeared as a cover story in GEN’s sister magazine, Clinical OMICs.)

Other articles from GEN in this supplement cover a broad range of issues, including enhancing and scaling up fundamental CRISPR genome-editing technology, and a range of new applications from engineering the pig genome for safer organ transplantation to various novel strategies in gene therapy.

 Articles Include:

  • A Dose of CRISPR: Can Gene Editing Cut It in the Clinic?
  • Genome Engineering: CRISPR Proving More User-Friendly
  • Using CRISPR to Improve Disease Modeling
  • Gifted Scientists Rapidly Advance CRISPR Operations
  • Genome Editing Explores New Depths
  • Applications of Novel CRISPR Tools

 

Previous

Next